Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.

Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators.

Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2.

2.

The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Welsh P, Poulter NR, Chang CL, Sever PS, Sattar N; ASCOT Investigators.

Hypertension. 2014 Mar;63(3):507-13. doi: 10.1161/HYPERTENSIONAHA.113.02204. Epub 2013 Dec 9.

3.

Long-term antihypertensive treatment fails to improve E/e' despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy.

Barron AJ, Hughes AD, Sharp A, Baksi AJ, Surendran P, Jabbour RJ, Stanton A, Poulter N, Fitzgerald D, Sever P, O'Brien E, Thom S, Mayet J; ASCOT Investigators.

Hypertension. 2014 Feb;63(2):252-8. doi: 10.1161/HYPERTENSIONAHA.113.01360. Epub 2013 Nov 11.

4.

Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

J Am Coll Cardiol. 2013 Aug 20;62(8):717-29. doi: 10.1016/j.jacc.2013.02.098.

5.

Impact of common variation in bone-related genes on type 2 diabetes and related traits.

Billings LK, Hsu YH, Ackerman RJ, Dupuis J, Voight BF, Rasmussen-Torvik LJ, Hercberg S, Lathrop M, Barnes D, Langenberg C, Hui J, Fu M, Bouatia-Naji N, Lecoeur C, An P, Magnusson PK, Surakka I, Ripatti S, Christiansen L, Dalgård C, Folkersen L, Grundberg E; MAGIC Investigators; DIAGRAM + Consortium; MuTHER Consortium; ASCOT Investigators; GEFOS Consortium, Eriksson P, Kaprio J, Ohm Kyvik K, Pedersen NL, Borecki IB, Province MA, Balkau B, Froguel P, Shuldiner AR, Palmer LJ, Wareham N, Meneton P, Johnson T, Pankow JS, Karasik D, Meigs JB, Kiel DP, Florez JC.

Diabetes. 2012 Aug;61(8):2176-86. Epub 2012 Jun 14.

6.

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR; ASCOT investigators.

J Hypertens. 2011 Oct;29(10):2004-13. doi: 10.1097/HJH.0b013e32834a8a42.

PMID:
21881528
7.

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; ASCOT Investigators.

Eur Heart J. 2011 Oct;32(20):2525-32. doi: 10.1093/eurheartj/ehr333. Epub 2011 Aug 28.

PMID:
21873710
8.

Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.

Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

Eur Heart J. 2012 Feb;33(4):486-94. doi: 10.1093/eurheartj/ehr262. Epub 2011 Jul 28.

9.

Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach.

Gupta AK, Prieto-Merino D, Dahlöf B, Sever PS, Poulter NR; ASCOT Investigators.

Diabet Med. 2011 Aug;28(8):941-7. doi: 10.1111/j.1464-5491.2011.03330.x.

PMID:
21749444
10.

Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

Collier DJ, Poulter NR, Dahlöf B, Sever PS, Wedel H, Buch J, Caulfield MJ; ASCOT Investigators.

J Hypertens. 2011 Mar;29(3):583-91. doi: 10.1097/HJH.0b013e328342c845.

PMID:
21297503
11.

Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.

Collier DJ, Poulter NR, Dahlöf B, Sever PS, Wedel H, Buch J, Caulfield MJ; ASCOT Investigators.

J Hypertens. 2011 Mar;29(3):592-9. doi: 10.1097/HJH.0b013e328342c8f7.

PMID:
21297502
12.

Wave reflection predicts cardiovascular events in hypertensive individuals independent of blood pressure and other cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudy.

Manisty C, Mayet J, Tapp RJ, Parker KH, Sever P, Poulter NR, Thom SA, Hughes AD; ASCOT Investigators.

J Am Coll Cardiol. 2010 Jun 29;56(1):24-30. doi: 10.1016/j.jacc.2010.03.030. Erratum in: J Am Coll Cardiol. 2011 Jan 4 ;57(1):117. Poulter, Neil H [corrected to Poulter, Neil R].

13.

High adherence and concordance within a clinical trial of antihypertensives.

Horne R, Clatworthy J, Hankins M; ASCOT Investigators.

Chronic Illn. 2010 Dec;6(4):243-51. doi: 10.1177/1742395310369018. Epub 2010 Jul 7.

PMID:
20610466
14.

Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.

Tapp RJ, Sharp A, Stanton AV, O'Brien E, Chaturvedi N, Poulter NR, Sever PS, Thom SA, Hughes AD, Mayet J; ASCOT Investigators.

J Am Coll Cardiol. 2010 Apr 27;55(17):1875-81. doi: 10.1016/j.jacc.2009.11.084.

15.

Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy.

Sharp AS, Tapp RJ, Thom SA, Francis DP, Hughes AD, Stanton AV, Zambanini A, O'Brien E, Chaturvedi N, Lyons S, Byrd S, Poulter NR, Sever PS, Mayet J; ASCOT Investigators.

Eur Heart J. 2010 Mar;31(6):747-52. doi: 10.1093/eurheartj/ehp498. Epub 2009 Nov 26.

PMID:
19942604
16.

Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.

Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD; ASCOT investigators; NORDIL investigators; BRIGHT Consortium.

Am J Hum Genet. 2009 Nov;85(5):628-42. doi: 10.1016/j.ajhg.2009.10.014.

17.

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR; ASCOT Investigators.

J Am Coll Cardiol. 2009 Sep 22;54(13):1154-61. doi: 10.1016/j.jacc.2009.04.087.

18.

Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).

Manisty C, Mayet J, Tapp RJ, Sever PS, Poulter N, McG Thom SA, Hughes AD; ASCOT Investigators.

Hypertension. 2009 Nov;54(5):1009-13. doi: 10.1161/HYPERTENSIONAHA.109.130914. Epub 2009 Aug 31.

19.

Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.

Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E; ASCOT Investigators.

J Hypertens. 2009 Apr;27(4):876-85. doi: 10.1097/HJH.0b013e328322cd62.

PMID:
19516185
20.

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT investigators.

Pharmacoeconomics. 2009;27(3):221-30. doi: 10.2165/00019053-200927030-00005.

PMID:
19354342

Supplemental Content

Loading ...
Support Center